BioRestorative Therapies, Inc.
About BioRestorative Therapies, Inc.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $359.7K
- Net income
- -$14.2M
- Total assets
- $4.1M
- Market cap
- $10.3M
- Gross margin
- 93.4%
- Operating margin
- -4350.1%
- Net margin
- -3959.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $359.7K
- Cost of revenue
- $23.8K
- Gross profit
- $335.9K
- Operating expenses
- $16.0M
- Operating income
- -$15.6M
- Net income
- -$14.2M
- EPS (basic)
- $-1.58
- EPS (diluted)
- $-1.58
Balance sheet
- Total assets
- $4.1M
- Current assets
- $3.1M
- Total liabilities
- $3.7M
- Current liabilities
- $3.7M
- Shareholders’ equity
- $356.7K
Cash flow
- Operating cash flow
- -$10.8M
- Investing cash flow
- $8.9M
- Financing cash flow
- $2.9M
- Net cash flow
- $963.3K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $10.3M
- EPS (diluted)
- $-1.58
- Shares outstanding
- 30.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 22, 1997
At a glance
- Reported a net loss of $14.2M in FY2025.
- Revenue grew 682% from FY2021 to FY2025.
- Gross margin of 93.4%, net margin -3959.4%.
- Trading 83% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioRestorative Therapies, Inc..
Write a review
News about BioRestorative Therapies, Inc.
News & sentiment via Polygon.io
